Elevation Oncology, Inc. announced that it has expanded its ongoing Phase 1 clinical trial of EO-3021 outside the United States, dosing the first patient in Japan. This trial is evaluating the safety, tolerability and preliminary anti-tumor activity of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Elevation Oncology's Phase 1 clinical trial (NCT05980416) is an open-label, multi-center dose escalation and expansion study to evaluate the safety, tolerability andiminary anti-tumor activity the EO-3021.

An additional objective of the study will be to assess the association of Claudin 18.2 expression and objective response. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. The company is evaluating EO-3021 in a Phase 1 study in patients with advanced, unre intersectable or metastatic solid tumors expected to express Claudin 18. 2 including gastric, gastroesphageal junction, pancreatic and esophageal cancers.

The company also exploring other opportunities through new or existing partnerships and business development opportunities to expand on oncology pipeline.